Exelixis Announces Detailed Results from Phase 3 COSMIC-313 Pivotal Trial in Patients with Previousl

– Cabozantinib in combination with nivolumab and ipilimumab significantly reduced the risk of disease progression or death compared with the combination of nivolumab and ipilimumab –– Median progression-free survival was not yet reached with the combination of cabozantinib, nivolumab and ipilimumab versus 11.3 month...

Related Keywords

Japan ,United States ,American ,Toni Choueiri ,Susan Hubbard ,Vickil Goodman ,Lindsay Treadway ,Nancy Kohlberg ,International Metastatic ,Daiichi Sankyo Company ,European Society Of Medical Oncology ,Takeda Pharmaceutical Company ,Nasdaq ,Database Consortium ,Exelixis Inc ,Public Affairs ,European Union ,Product Development Medical Affairs ,Facebook ,Dana Farber Cancer Institute ,Radiology Committee ,Bristol Myers Squibb ,American Cancer Society ,Genentech Inc ,Professor Of Medicine At Harvard Medical School ,Lank Center ,Exchange Commission ,Presidential Symposium ,Medical Oncology ,Genitourinary Oncology ,Nancy Kohlberg Chair ,Harvard Medical ,Response Evaluation Criteria ,Solid Tumors ,Blinded Independent Radiology Committee ,Executive Vice President ,Product Development ,Medical Affairs ,Chief Medical Officer ,Ipsen Pharma ,Takeda Pharmaceutical Company Limited ,Hypertensive Crisis ,Plantar Erythrodysesthesia ,Impaired Wound Healing ,Posterior Leukoencephalopathy Syndrome ,Fetal Toxicity ,Prescribing Information ,Exelixi Quarterly Report ,Cancer Society ,Cancer Facts ,Resources Report ,Renal Cell ,